Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2001

View Archived Issues

Medical Discoveries' MDI-P shows efficacy as microbicide in preclinical studies

Ivax updates proprietary product pipeline

Meditech licenses Solaraze from SkyePharma

Drospirenone-containing contraceptive first launched in Germany

January launch for MyoBloc injectable solution for cervical dystonia

Corixa and CoPharma enter collaboration for novel cardioprotectant

CVT's phytopharmaceutical for cold and flu enters phase II

Generex completes joint venture with Elan

Schering-Plough submits two new applications for desloratadine in the E.U.

Patient enrollment complete in phase I/II Chrysalin trial

Wyeth-Ayerst seeks FDA approval of new indication of Alesse

Potential new therapy for erectile dysfunction presented by Dong-A

FDA denies approval of Aronex's Atragen for APL

Ciba Vision pharmaceutical unit is now Novartis Ophthalmics

Maxim's NDA for histamine hydrochloride deemed unapprovable by FDA

Modex completes patient enrollment in EpiDex phase II trial

Biogen's Avonex meets primary endpoint in study of secondary progressive MS

Genzyme General begins treating Fabry's disease patients; global disease registry launched

Two new clinical trials commence with Genasense for leukemia

Patent issued to Sigma-Tau covering L-carnitine or alkanoyl derivatives and statin combinations

Genentech describes new series of DR4 modulators for cancer and immune-related diseases

Sankyo presents new anti-HIV agents

MMP inhibitors from Pfizer reportedly useful for inflammatory disorders and cancer

Celltech Group claims new series of squaric acid derivatives

Novel tachykinin NK1 receptor antagonists disclosed by Roche

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...